Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Implications of efavirenz for neuropsychiatry: a review.

Cavalcante GI, Capistrano VL, Cavalcante FS, Vasconcelos SM, Macêdo DS, Sousa FC, Woods DJ, Fonteles MM.

Int J Neurosci. 2010 Dec;120(12):739-45. doi: 10.3109/00207454.2010.520541. Epub 2010 Oct 22. Review.

PMID:
20964556
2.

Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring.

Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, Martín-Hidalgo A.

Clin Infect Dis. 2005 Dec 1;41(11):1648-53. Epub 2005 Oct 19.

PMID:
16267739
3.

Potential benefits of cyproheptadine in HIV-positive patients under treatment with antiretroviral drugs including efavirenz.

Dabaghzadeh F, Khalili H, Ghaeli P, Dashti-Khavidaki S.

Expert Opin Pharmacother. 2012 Dec;13(18):2613-24. doi: 10.1517/14656566.2012.742887. Epub 2012 Nov 10. Review.

PMID:
23140169
4.

[Acute psychosis as a side effect of efavirenz therapy with metabolic anomalies: an important differential diagnosis of HIV-associated psychoses].

Hinsch MC, Reichelt D, Husstedt IW.

Nervenarzt. 2014 Oct;85(10):1304-8. doi: 10.1007/s00115-014-4157-9. German.

PMID:
25200885
5.

HIV and mental illness in Malawi and the neuropsychiatric sequelae of efavirenz.

Drury A, Gleadow-Ware S, Gilfillan S, Ahrens J.

Malawi Med J. 2018 Mar;30(1):40-45. doi: 10.4314/mmj.v30i1.9. Review.

6.

[Evidence-based therapeutic drug monitoring for efavirenz].

Solas C, Gagnieu MC; roupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.

Therapie. 2011 May-Jun;66(3):197-205. doi: 10.2515/therapie/2011033. Epub 2011 Aug 9. Review. French.

PMID:
21819803
7.

AIDS dementia-related psychosis: is there a window of vulnerability?

el-Mallakh RS.

AIDS Care. 1992;4(4):381-7. Review.

PMID:
1493145
8.

[Apropos of atypical melancholia with Sustiva (efavirenz)].

Lang JP, Halleguen O, Picard A, Lang JM, Danion JM.

Encephale. 2001 May-Jun;27(3):290-3. French.

PMID:
11488260
9.

Severe mental illness and HIV-related medical and neuropsychiatric sequelae.

McDaniel JS, Purcell DW, Farber EW.

Clin Psychol Rev. 1997;17(3):311-25. Review.

PMID:
9160179
10.

Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review.

Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, González-García M, Moltó J, Negredo E, Clotet B.

AIDS Rev. 2009 Apr-Jun;11(2):103-9. Review.

PMID:
19529750
11.

Long-term efficacy and safety of TDM-assisted combination of voriconazole plus efavirenz in an AIDS patient with cryptococcosis and liver cirrhosis.

Carbonara S, Regazzi M, Ciracì E, Villani P, Stano F, Cusato M, Heichen M, Monno L.

Ann Pharmacother. 2009 May;43(5):978-84. doi: 10.1345/aph.1L607. Epub 2009 Apr 21.

PMID:
19383934
12.

Clinical implications of HIV-1 drug resistance in the neurological compartment.

Antinori A, Cingolani A, Giancola ML, Forbici F, De Luca A, Perno CF.

Scand J Infect Dis Suppl. 2003;106:41-4. Review.

PMID:
15000582
13.

[Hepatitis C, interferon a and depression: main physiopathologic hypothesis].

Vignau J, Karila L, Costisella O, Canva V.

Encephale. 2005 May-Jun;31(3):349-57. Review. French.

PMID:
16142050
14.

Liver toxicity associated with antiretroviral therapy including efavirenz or ritonavir-boosted protease inhibitors in a cohort of HIV/hepatitis C virus co-infected patients.

Neukam K, Mira JA, Ruiz-Morales J, Rivero A, Collado A, Torres-Cornejo A, Merino D, de Los Santos-Gil I, Macías J, González-Serrano M, Camacho A, Parra-García G, Pineda JA; SEGURIDAD HEPÁTICA Study Team of the Grupo HEPAVIR de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI).

J Antimicrob Chemother. 2011 Nov;66(11):2605-14. doi: 10.1093/jac/dkr357. Epub 2011 Sep 7.

PMID:
21903660
15.

Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.

Wintergerst U, Hoffmann F, Jansson A, Notheis G, Huss K, Kurowski M, Burger D.

J Antimicrob Chemother. 2008 Jun;61(6):1336-9. doi: 10.1093/jac/dkn112. Epub 2008 Mar 13.

PMID:
18343800
16.

Neurological and psychiatric tolerability of rilpivirine (TMC278) vs. efavirenz in treatment-naïve, HIV-1-infected patients at 48 weeks.

Mills AM, Antinori A, Clotet B, Fourie J, Herrera G, Hicks C, Madruga JV, Vanveggel S, Stevens M, Boven K; ECHO and THRIVE study groups.

HIV Med. 2013 Aug;14(7):391-400. doi: 10.1111/hiv.12012. Epub 2013 Jan 9.

18.

HIV antiretroviral drug Efavirenz induces anxiety-like and depression-like behavior in rats: evaluation of neurotransmitter alterations in the striatum.

Cavalcante GI, Chaves Filho AJ, Linhares MI, de Carvalho Lima CN, Venâncio ET, Rios ER, de Souza FC, Vasconcelos SM, Macêdo D, de França Fonteles MM.

Eur J Pharmacol. 2017 Mar 15;799:7-15. doi: 10.1016/j.ejphar.2017.02.009. Epub 2017 Feb 8.

PMID:
28188763
19.

[Treatment of HIV infection from the neurologic viewpoint. Therapy must reach the brain].

von Giesen HJ, Köller H, Arendt G.

MMW Fortschr Med. 2002 Apr 9;144 Suppl 1:46-50. German.

PMID:
12043074
20.

Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Csajka C, Marzolini C, Fattinger K, Décosterd LA, Fellay J, Telenti A, Biollaz J, Buclin T.

Clin Pharmacol Ther. 2003 Jan;73(1):20-30.

PMID:
12545140

Supplemental Content

Support Center